SCHEMBL1786624

SCHEMBL1786624

Cc1nn(N)c(=O)c2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.56
LMNA P02545 1/20 0.54
RAB9A P51151 7/20 0.51
NPC1 O15118 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
GAA P10253 3/20 0.51
KDM4E B2RXH2 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.47
TSHR P16473 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HSP90AA1 P07900 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1932012 0.86 ATM (0.45) NPSR1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL434996 0.78 NPSR1 (0.58) NPSR1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL1787409 0.76 SMN1; SMN2 (0.47) NPSR1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL1789865 0.76 SMN1; SMN2 (0.41) NPSR1LMNARAB9ASMN1; SMN2GAA
SCHEMBL1791327 0.75 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2GAAALDH1A1MEN1
SCHEMBL3652714 0.75 GLS (0.50) NPSR1LMNARAB9ANPC1SMN1; SMN2
SCHEMBL12877767 0.73 LMNA (0.64) NPSR1LMNARAB9ASMN1; SMN2KMT2A
SCHEMBL1788116 0.73 ALDH1A1 (0.57) NPSR1LMNARAB9ASMN1; SMN2GAA
SCHEMBL14917566 0.73 RAB9A (0.76) NPSR1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL13721065 0.72 SMN1; SMN2 (0.44) NPSR1RAB9ASMN1; SMN2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629143-B2 Potassium channel modulators ABBVIE INC. (US) 2014-01-14 US disclosed
EP-2504317-A1 POTASSIUM CHANNEL MODULATORS Abbott Laboratories (US) 2012-10-03 EP disclosed
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124642-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNQ3 NPSR1 505/4885LMNA 1106/4885RAB9A 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.